Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Cells ; 11(10)2022 05 17.
Article in English | MEDLINE | ID: mdl-35626701

ABSTRACT

Huntington's disease (HD) is a neurodegenerative inherited genetic disorder, which leads to the onset of motor, neuropsychiatric and cognitive disturbances. HD is characterized by the loss of gamma-aminobutyric acid (GABA)ergic medium spiny neurons (MSNs). To date, there is no treatment for HD. Mesenchymal stem cells (MSCs) provide a substantial therapeutic opportunity for the HD treatment. Herein, we investigated the therapeutic potential of human immature dental pulp stem cells (hIDPSC), a special type of MSC originated from the neural crest, for HD treatment. Two different doses of hIDPSC were intravenously administrated in a subacute 3-nitropropionic acid (3NP)-induced rat model. We demonstrated hIDPSC homing in the striatum, cortex and subventricular zone using specific markers for human cells. Thirty days after hIDPSC administration, the cells found in the brain are still express hallmarks of undifferentiated MSC. Immunohistochemistry quantities analysis revealed a significant increase in the number of BDNF, DARPP32 and D2R positive stained cells in the striatum and cortex in the groups that received hIDPSC. The differences were more expressive in animals that received only one administration of hIDPSC. Altogether, these data suggest that the intravenous administration of hIDPSCs can restore the BDNF, DARPP32 and D2R expression, promoting neuroprotection and neurogenesis.


Subject(s)
Brain-Derived Neurotrophic Factor , Dopamine and cAMP-Regulated Phosphoprotein 32 , Huntington Disease , Stem Cell Transplantation , Stem Cells , Animals , Brain-Derived Neurotrophic Factor/genetics , Dental Pulp/cytology , Disease Models, Animal , Dopamine and cAMP-Regulated Phosphoprotein 32/genetics , Humans , Huntington Disease/genetics , Huntington Disease/therapy , Infusions, Intravenous , Rats , Stem Cells/cytology
2.
Cells ; 9(11)2020 11 23.
Article in English | MEDLINE | ID: mdl-33238381

ABSTRACT

Although papillary thyroid carcinoma (PTC) has a good prognosis, 20-90% of patients show metastasis to regional lymph nodes and 10-15% of patients show metastasis to distant sites. Metastatic disease represents the main clinical challenge that impacts survival rate. We previously showed that LIMD2 was a novel metastasis-associated gene. In this study, to interrogate the role of LIMD2 in cancer invasion and metastasis, we used CRISPR-mediated knockout (KO) of LIMD2 in PTC cells (BCPAP and TPC1). Western blot and high-content screening (HCS) analysis confirmed functional KO of LIMD2. LIMD2 KO reduced in vitro invasion and migration. Ultrastructural analyses showed that cell polarity and mitochondria function and morphology were restored in LIMD2 KO cells. To unveil the signals supervising these phenotypic changes, we employed phospho-protein array. Several members of the MAPK superfamily showed robust reduction in phosphorylation. A Venn diagram displayed the overlap of kinases with reduced phosphorylation in both cell lines and showed that they were able to initiate or sustain the epithelial-mesenchymal transition (EMT) and DNA damage checkpoint. Flow cytometry and HCS validation analyses further corroborated the phospho-protein array data. Collectively, our findings show that LIMD2 enhances phosphorylation of kinases associated with EMT and invasion. Through cooperation with different kinases, it contributes to the increased genomic instability that ultimately promotes PTC progression.


Subject(s)
Mitogen-Activated Protein Kinase Kinases/metabolism , Neoplasm Proteins/therapeutic use , Thyroid Cancer, Papillary/genetics , Cell Line, Tumor , Epithelial-Mesenchymal Transition , Female , Humans , Male , Neoplasm Metastasis , Neoplasm Proteins/pharmacology , Thyroid Cancer, Papillary/pathology
3.
Cell Med ; 7(3): 95-108, 2015 Oct 01.
Article in English | MEDLINE | ID: mdl-26858898

ABSTRACT

Acute renal failure (ARF) is a common renal disease that can lead to high mortality. Recovery from ARF occurs with the replacement of necrotic tubular cells by functional tubular epithelial cells and the normalization of microvascular endothelial cell function in the peritubular capillaries. Conventional therapeutic techniques are often ineffective against ARF. Hence, stem cell therapies, which act through multiple trophic and regenerative mechanisms, are encouraging. We investigated the homing of human immature dental pulp stem cells (IDPSCs) after endovenous (EV) or intraperitoneal (IP) injection, in immunocompetent Wistar rats with ARF induced by intramuscular injection of glycerol, without the use of immunosuppression. The cells, which had been cryopreserved for 6 years, were CD105(+), CD73(+), CD44(+), and partly, STRO-1(+) and CD146(+), and presented unaltered mesoderm differentiation potential. The presence of these cells in the tubular region of the kidney and in the peritubular capillaries was demonstrated. These cells accelerate tubular epithelial cell regeneration through significant increase of Ki-67-immunoreactive cells in damaged kidney. Flow cytometry analysis confirmed that IDPSCs home to the kidneys (EV 34.10% and IP 33.25%); a lower percentage of cells was found in the liver (EV 19.05% and IP 9.10%), in the muscles (EV 6.30% and IP 1.35%), and in the lungs (EV 2.0% and IP 1.85%). After infusion into rat, these cells express pericyte markers, such as CD146(+), STRO-1(+), and vascular endothelial growth factor (VEGF(+)). We found that IDPSCs demonstrate renotropic and pericyte-like properties and contributed to restore renal tubule structure in an experimental rat ARF model.

4.
Toxicol Appl Pharmacol ; 266(3): 385-98, 2013 Feb 01.
Article in English | MEDLINE | ID: mdl-23238560

ABSTRACT

Breast cancer is the world's leading cause of death among women. This situation imposes an urgent development of more selective and less toxic agents. The use of natural molecular fingerprints as sources for new bioactive chemical entities has proven to be a quite promising and efficient method. Capsaicin, which is the primary pungent compound in red peppers, was reported to selectively inhibit the growth of a variety tumor cell lines. Here, we report for the first time a novel synthetic capsaicin-like analogue, RPF101, which presents a high antitumor activity on MCF-7 cell line, inducing arrest of the cell cycle at the G2/M phase through a disruption of the microtubule network. Furthermore, it causes cellular morphologic changes characteristic of apoptosis and a decrease of Δψm. Molecular modeling studies corroborated the biological findings and suggested that RPF101, besides being a more reactive molecule towards its target, may also present a better pharmacokinetic profile than capsaicin. All these findings support the fact that RPF101 is a promising anticancer agent.


Subject(s)
Adenocarcinoma/drug therapy , Apoptosis/drug effects , Breast Neoplasms/drug therapy , Capsaicin/analogs & derivatives , G2 Phase Cell Cycle Checkpoints/drug effects , M Phase Cell Cycle Checkpoints/drug effects , Microtubules/drug effects , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Apoptosis/physiology , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Capsaicin/chemical synthesis , Capsaicin/chemistry , Capsaicin/pharmacology , Cell Survival/drug effects , Cell Survival/physiology , DNA Fragmentation , Female , Flow Cytometry , G2 Phase Cell Cycle Checkpoints/physiology , Humans , M Phase Cell Cycle Checkpoints/physiology , MCF-7 Cells , Magnetic Resonance Spectroscopy , Mass Spectrometry , Membrane Potential, Mitochondrial/drug effects , Membrane Potential, Mitochondrial/physiology , Microscopy, Confocal , Microtubules/metabolism , Models, Molecular
SELECTION OF CITATIONS
SEARCH DETAIL